EUCTR2008-003539-19-NL进行中（未招募）1 期
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). - CHEST-2
Bayer HealthCare AG, Bayer Vital GmbH, D-51368 Leverkusen0 个研究点目标入组 270 人开始时间: 2008年10月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients who have completed 16 weeks of treatment in the double blind trial CHEST-1
- •Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient’s participating in another clinical trial
- •Patients who have an ongoing serious adverse event from CHEST-1 that is assessed as related to BAY 63-2521 are not allowed to participate in the extension trial.
- •Pregnant women (i.e. positive serum ß-human-chorionic-gonadotropin test or other signs of pregnancy) or breast feeding women, or women with childbearing potential not using a combination of safe contraception methods throughout the study.
- •Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator or the sponsor.
- •Pertinent non compliance with the conditions for the trial or instructions by the investigator during CHEST-1 participation.
- •Patients with hypersensitivity to the investigational drug or inactive constituents.
研究者
相似试验
已完成
3 期
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH).Pulmonary hypertension / increased blood pressure in the lungs1001928010037454NL-OMON35533Bayer10
撤回
3 期
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).Pulmonary hypertension / increased blood pressure in the lungs1001928010037454NL-OMON37076Bayer10
进行中（未招募）
1 期
ong-term study to collect additional information to evaluate the safety and tolerability of BAY 63-2521 in different dosesChronic Thromboembolic Pulmonary HypertensionMedDRA version: 14.1Level: LLTClassification code 10037406Term: Pulmonary hypertension secondarySystem Organ Class: 100000004855EUCTR2008-003539-19-DEBayer HealthCare AG,270
进行中（未招募）
1 期
ong-term study to collect additional information to evaluate the safety and tolerability of BAY 63-2521 in different dosesPulmonary Arterial Hypertension (PAH)MedDRA version: 19.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2008-003610-94-PTBayer AG462
进行中（未招募）
不适用
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-2Pulmonary Arterial Hypertension (PAH)MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-003610-94-IEBayer HealthCare AG462